{"schema_version":"secwatch.filing_event.v1","accession":"0001649094-26-000005","form_type":"8-K","ticker":"PCVX","cik":"0001649094","company_name":"Vaxcyte, Inc.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.752479+00:00","generated_at":"2026-05-16T00:49:23.012620+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering","bullets":["Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).","Cash, equivalents, investments $2.44B at Dec 31, 2025; $632.5M gross from Feb 2026 public offering.","VAX-31 adult Phase 3 program (OPUS-1/2/3) underway; topline OPUS-1 data expected Q4 2026, OPUS-2/3 in H1 2027.","VAX-31 infant Phase 2 dose-finding study (900 infants) fully enrolled; data from series and booster expected by H1 2027.","Plan to initiate Phase 1 study for Group A Strep vaccine candidate VAX-A1 in 2026; dedicated Lonza facility completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001649094-26-000005","json":"https://secwatch.observer/filing/0001649094-26-000005.json","markdown":"https://secwatch.observer/filing/0001649094-26-000005.md","text":"https://secwatch.observer/filing/0001649094-26-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/0001649094-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:49:23.012620+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}